about
Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex.The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-LactamsPulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and preventionOn the functional interchangeability, oxidant versus reductant, of members of the thioredoxin superfamilyA selection for mutants that interfere with folding of Escherichia coli thioredoxin-1 in vivo.Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.Enterococcus faecalis prophage dynamics and contributions to pathogenic traitsThe search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae.Bacterial sensing of bacteriophages in communities: the search for the Rosetta stone.Quality and safety requirements for sustainable phage therapy products.Next-Generation "-omics" Approaches Reveal a Massive Alteration of Host RNA Metabolism during Bacteriophage Infection of Pseudomonas aeruginosa.Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestinePredicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice.Tools from viruses: bacteriophage successes and beyond.A bacteriophage journey at the European Medicines Agency.Folded HasA inhibits its own secretion through its ABC exporterSynergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen.Comparative transcriptomics analyses reveal the conservation of an ancestral infectious strategy in two bacteriophage genera.[Phage therapy: a realistic weapon against multidrug resistant bacteria].Bacteriophages Targeting Adherent Invasive Escherichia coli Strains as a Promising New Treatment for Crohn's Disease.Commentary: Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro.Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages.Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.Viruses of Microbes.Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.In Vivo Bacteriophage Biodistribution.Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice.[Experimental phage therapy in the beginning of the 21st century].Meeting report of the European Molecular Biology Organization (EMBO) Symposium 'Viruses of Microbes II', Brussels, July 2012.Ligand delivery by haem carrier proteins: the binding of Serratia marcescens haemophore to its outer membrane receptor is mediated by two distinct peptide regions.The Gut Microbiota Facilitates Drifts in the Genetic Diversity and Infectivity of Bacterial Viruses.Homology between a genetic locus (mdoA) involved in the osmoregulated biosynthesis of periplasmic glucans in Escherichia coli and a genetic locus (hrpM) controlling pathogenicity of Pseudomonas syringae.Key issues in phage therapy: a report of a dedicated workshop at the Viruses of Microbes II meeting.Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.[Phagotherapy: a nightmare for bacteria, a dream for physicians?]."French Phage Network"-Third Meeting Report.[Organizers' report]The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?The Diversity of Bacterial Lifestyles Hampers Bacteriophage Tenacity
P50
Q30390256-DE55A28D-16B4-4333-B4C1-052182917CA7Q33696025-FADD7C77-3D42-462C-91FF-0E4B93600AF5Q33828309-8AE9259C-D140-4AB3-B936-1046B582EF2CQ33993677-04C1C4D4-F92C-4CF1-9092-49BF68126712Q34245202-A3A73C7A-EE2F-47DC-BDAB-DABF39E821A4Q34625525-BD53927D-DA26-4A4C-9B37-5AD0E0D6FC7CQ34765413-C527B184-7AF9-42F8-9F1D-E67637F9E34BQ35023371-ADDF3A18-93B7-4349-93D1-2C0A0450AB9FQ35192652-750EEDA5-904A-47AD-87D9-8A3D6B75B2BDQ35674419-6B305D11-F179-4A82-9694-DD08D35792E4Q36068358-4B561AA6-3A05-4D42-A720-43C5B47BF734Q36396212-F368BAEF-DD31-4059-B9C4-41CA0CAD1A6EQ37335751-0800A5C0-859A-4FFA-BA9C-7DEBE99A6820Q38022879-0D58B40B-AECB-44CF-8318-0C6A617FF454Q38051893-A49024D3-4C7E-4856-AC39-F02BBB7F1E98Q38560900-75C18396-54C7-4519-8373-C77B7EC7ED18Q39645637-4B79EA1A-2CD0-4845-9C34-5E8FAEC93A0BQ40136034-101F87C0-052A-4519-8D40-FE5AB5C53068Q40204030-51DE6AC4-BCD3-4974-ABDE-6B87D31897C5Q40204267-03CE06BD-50DA-419D-A9EE-E14F717DB1CDQ40355471-176F3D4F-B497-4B54-AB14-3EF29D88D616Q40604790-E68D697C-83FE-4FD1-8EF9-D790D6AE24EFQ41389690-3A3968F1-6F89-4677-AF0A-39D25175251CQ42213051-81E6594A-C62E-46E2-99CF-FBB987FABFA9Q42365588-0E76E221-96E4-438F-824E-C215BEC9E7EAQ43028377-257FA2C4-70D9-4843-8A5B-88589AF05E28Q43033569-6EA76F3B-7419-4D13-BC85-CA99757AC55FQ43033611-13233279-38F3-415D-9E9B-7774938B53B4Q43742689-348B023E-E753-4C82-BFCC-F2E9455D7CACQ43974687-DAB3F9EF-DA4A-4624-A9A6-78DFC9AB7E24Q44594941-29E0E5BD-514F-4F22-9740-609780D2A596Q47415707-39942316-D094-4B64-B7BD-84C67F069692Q48100281-7B08EFA4-81EB-4BD7-BD39-D7AD8385A0EDQ51878296-F6615237-C31B-4BC4-9B1F-A88F4C78A650Q52604672-9AFC9FDD-AD7A-4A78-BE54-2F0E50071132Q54298905-60F70693-8FA2-4E61-8E8F-ADB71C684E3CQ55170549-C718A4BA-7B30-446F-8D83-07CE6C83A001Q57101186-78048B58-9E8B-47C2-A12A-BDD6F6AB80BDQ57923584-AF297C60-5FCD-498B-9BF0-7AABDAC04F2FQ57952638-4ECE6B33-382B-4361-B7DB-B1FB5DCD6F79
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Laurent Debarbieux
@ast
Laurent Debarbieux
@en
Laurent Debarbieux
@es
Laurent Debarbieux
@nl
Laurent Debarbieux
@sl
type
label
Laurent Debarbieux
@ast
Laurent Debarbieux
@en
Laurent Debarbieux
@es
Laurent Debarbieux
@nl
Laurent Debarbieux
@sl
prefLabel
Laurent Debarbieux
@ast
Laurent Debarbieux
@en
Laurent Debarbieux
@es
Laurent Debarbieux
@nl
Laurent Debarbieux
@sl
P106
P21
P2798
P31
P496
0000-0001-6875-5758